Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking the third company to be accepted for IPO this year [1] Group 1: Company Overview - Jianxin Superconducting focuses on the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment [2] - The company was established in December 2013 and completed its share reform in November 2022, headquartered in Cixi, Ningbo, Zhejiang Province [5] - The founder, Xu Jianyi, holds 41.51% of the shares, with his family controlling a total of 59.92% of the voting rights [5][6] Group 2: Financial Performance - The company's revenue for 2022, 2023, and 2024 was 359 million, 451 million, and 425 million yuan respectively, with net profits of 34.63 million, 48.73 million, and 55.78 million yuan [12] - In 2024, the revenue is expected to decline due to factors such as the impact of medical equipment policies and a slowdown in the domestic medical procurement market [12] - The gross profit margins for the last three years were 19.56%, 22.84%, and 24.94%, which are relatively low compared to peers [14] Group 3: Market Position - Jianxin Superconducting holds approximately 4.2% of the global market share for superconducting magnets, ranking fifth globally and second among domestic companies [18][28] - The global MRI equipment market has grown from $7.5 billion in 2015 to $11.1 billion in 2024, with a compound annual growth rate (CAGR) of 4.5% [23] - The Chinese MRI equipment market has increased from 10.45 billion yuan in 2015 to 16.6 billion yuan in 2024, with a CAGR of 5.3% [23] Group 4: Product and R&D - The company has developed a product matrix that includes various types of superconducting magnets, with a notable increase in revenue from non-liquid helium products [9][10] - Jianxin Superconducting's R&D team includes members with experience from major medical device companies, enhancing its innovation capabilities [7] - The company has invested a total of 72.4 million yuan in R&D over the past three years, accounting for 5.86% of its cumulative revenue [16] Group 5: Future Prospects - The company plans to raise 865 million yuan through its IPO, with 90 million yuan allocated for working capital [29] - Despite recent cash dividends totaling approximately 20 million yuan annually, the company faces challenges in maintaining cash flow due to rising inventory levels [17][29]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 证券代码：430300 证券简称：辰光医疗 公告编号：2025-050 上海辰光医疗科技股份有限公司 投资者关系活动记录表 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 5 月 13 日 下午 15:00-17:00 活动地点：上海辰光医疗科技股份有限公司通过全景网"投资者关系互动平 台"（https://ir.p5w.net）采用网络远程的方式召开 2024 年业绩说明会。 参会单位及人员：通过网络方式参与公司本次业绩说明会的投资者 上市公司接待人员： 董事长、总经理：王杰 先生 董事、副总经理：王为 先生 董事会秘书：于玲 女士 财务负责人：郑云 女士 公司保荐代表人：韩佳 先生 三、 投资者关系活动主要内容 公司就投资者在本次业绩说明会中提出的问题进行了回复： 1、公司未来发展的规划是什么？公司连续两年业绩不佳，请问 2 ...

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. has recently received acceptance for its IPO application on the Sci-Tech Innovation Board, with significant revenue dependence on its largest customer, Fujifilm Group, which is expected to contribute over 40% of the company's revenue in 2024 [1][3]. Revenue Dependence - The company relies heavily on its top five customers, with sales to these clients accounting for approximately 73.75%, 76.68%, and 79.62% of total revenue from 2022 to 2024 [3]. - Sales to Fujifilm Group specifically are projected to represent 34.2%, 44.2%, and 42.71% of total revenue for the years 2022, 2023, and 2024, respectively [3][4]. Financial Performance - Jianxin Superconducting's revenue for 2022, 2023, and 2024 is approximately CNY 359 million, CNY 451 million, and CNY 425 million, respectively, with net profits of CNY 34.63 million, CNY 48.73 million, and CNY 55.78 million [3]. - The company's gross profit margins are significantly lower than industry peers, with margins of 19.56%, 22.84%, and 24.94% compared to industry averages of 46.27%, 45.59%, and 45.17% for the same periods [4]. Inventory and Cash Dividends - The company has experienced a substantial increase in inventory, with values of approximately CNY 182 million, CNY 236 million, and CNY 319 million at the end of each reporting period [4]. - Jianxin Superconducting has distributed significant cash dividends prior to the IPO, with amounts of CNY 19.99 million each year from 2022 to 2024, representing 57.74%, 41.04%, and 35.85% of net profits, respectively [5]. R&D Investment - The company's R&D expense ratio is notably lower than that of comparable companies, with rates of 5.66%, 5.42%, and 6.5% against industry averages of 14.44%, 14.41%, and 18.36% [7]. - Jianxin Superconducting plans to increase R&D investment, with part of the IPO proceeds allocated for this purpose to support new product and technology development [7]. Ownership Structure - As of the signing of the prospectus, the controlling shareholder, Xu Jianyi, holds 41.51% of the company, with the actual controllers collectively holding 59.92% of the voting rights [6].

Core Viewpoint - Chuangguang Medical's stock closed at 18.55 yuan on May 12, marking a 3.57% increase, with a latest price-to-book ratio of 7.25, reaching a 15-day low, and a total market capitalization of 1.592 billion yuan [1] Group 1: Company Overview - Chuangguang Medical focuses on the research, development, production, and sales of superconducting MRI systems and specialized magnets in high-tech fields [1] - The company has been recognized as a high-tech enterprise with various accolades, including "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" at both municipal and national levels [1] Group 2: Financial Performance - For Q1 2025, Chuangguang Medical reported revenue of 25.0744 million yuan, representing a year-on-year increase of 20.21% [1] - The net profit for the same period was -8,582,701.78 yuan, showing a year-on-year decline of 5.22%, with a gross profit margin of 30.84% [1] Group 3: Market Activity - On May 12, the net inflow of main funds into Chuangguang Medical was 834,400 yuan, with a total inflow of 7.1875 million yuan over the past five days [1]

Group 1 - The pharmaceutical sector is a key focus for institutional investors, with brokers increasing their investments and research efforts in this area [1] - As of the end of Q1, 14 brokerage firms were among the top ten shareholders of 25 pharmaceutical companies, holding a total of 508 million shares valued at 4.118 billion [1] - In Q1, brokers frequently adjusted their holdings in the pharmaceutical sector, initiating positions in 10 stocks, increasing holdings in 3, and reducing holdings in 11 [1][2] Group 2 - New positions taken by brokers in Q1 included 1.162 billion for Yihe Jiaye and 1.13 billion for Borui Pharmaceutical, with significant holdings also in Jia Ying Pharmaceutical and Chuangguang Medical [2] - Brokers have been actively conducting on-site research to gather firsthand information about the pharmaceutical sector, with over 50 brokers focusing on companies like Aibo Medical and Wanjian Medical [2] - A total of 23 pharmaceutical stocks have been recommended by brokers this month, with notable mentions including Baiji Shenzhou and Heng Rui Pharmaceutical, indicating strong long-term growth prospects [3] Group 3 - The pharmaceutical sector is expected to see a recovery in profitability by 2025, with current PE valuations at historical lows, suggesting potential for excess returns compared to the broader market [3] - Analysts recommend focusing on high-growth, strong recovery, and new expectations for pharmaceutical investments in 2025, particularly in innovative drugs and medical devices [4] - Investment strategies should prioritize companies with significant product advantages and healthy balance sheets, especially those with global sales potential [4]

证券代码：430300 证券简称：辰光医疗 公告编号：2025-048 上海辰光医疗科技股份有限公司 关于公司取得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"、"辰光医疗"）近日取 得国家知识产权局颁发 2 项《发明专利证书》，具体情况如下： 1、发明名称：一种用于磁共振成像的零焊点柔性射频线圈结构 专利号：ZL 2021 1 0508355.1 专利申请日：2021 年 04 月 27 日 专利权人：上海辰光医疗科技股份有限公司 地址：201707 上海市青浦区华青路 1269 号 授权公告号：CN 113109750 B 该专利属于医用磁共振技术领域。本发明提供一种用于磁共振成像的零焊点 柔性射频线圈结构，进一步降低磁共振射频线圈的厚度和重量，提高其可靠性、 柔软性和舒适度。 2、发明名称：一种分布式电容的磁共振射频发射线圈结构 专利号：ZL 2021 1 0728221.0 （二）《发明专利证书》（证书号第 790 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-049 上海辰光医疗科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 在北京证券交易所信息披露平台（www.bse.cn）披露了《2024 年年度报告》（公 告编号：2025-023），为方便广大投资者更深入了解公司 2024 年年度经营业绩的 具体情况，加强与投资者的互动交流，公司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 13 日（星期二）下午 15：00-17:00。 （二）会议召开地点 本次年报业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投 资者关系互动平台"（http://ir.p5w.net）参与本次年报业绩说明会。 三、 参加人员 董事长、总经理：王杰 先生 董事、副总经理：王为 先生 董事会 ...

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and specialized magnets in high-tech fields [1] - The company has a market capitalization of 1.509 billion yuan and a latest price-to-book ratio of 6.88 [1] - The company reported a revenue of 25.0744 million yuan in Q1 2025, representing a year-on-year increase of 20.21%, while the net profit was -8.5827 million yuan, a year-on-year decrease of 5.22% [1] Group 2 - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and New" small giant enterprise [1] - The company’s sales gross margin stands at 30.84% [1] - The company experienced a net inflow of 8.4283 million yuan in main funds on May 6, with a total inflow of 15.8293 million yuan over the past five days [1]

证券代码：430300 证券简称：辰光医疗 公告编号：2025-046 上海辰光医疗科技股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2025 年 4 月 22 日以书面、电话和微信方 式发出 5.会议主持人：监事长 ZHAO HUAWEI（赵华炜）先生 6.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律法规、规范性文件和《公司章程》 的规定，所做决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《2025 年第一季度报告》议案 1.议案内容： 根据相关法律法规、规范性文件及《公司章程》规定，结合公司 2025 年第 一季度的经营情况，公司编 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-045 上海辰光医疗科技股份有限公司 第五届董事会第十八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 3.会议召开方式：现场会议 （二）会议出席情况 4.发出董事会会议通知的时间和方式：2025 年 4 月 22 日以书面、电话和微 信方式发出 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 5.会议主持人：董事长 王杰先生 6.会议列席人员：监事、高级管理人员 （一）审议通过《2025 年第一季度报告》 1.议案内容： 7.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律法规、规范性文件和《公司章程》 的规定。 3.回避表决情况： 本议案不涉及回避表决。 4.提交股东会表决情况： 本议案无需提交股东会审议。 根据相关法律 ...